Dr Winter ***Retired***

http://venturearchitecture.com/venture-architecture-celebrates-sweet-16-anniversary/

Combs-la-Ville PRIVATE

PERSONAL

PROFESSIONAL

PHYSICIAN LEVEL SERVICE

NORTH IDAHO LOCATION – EASY ACCESS –

POST FALLS off I-90 Seltice

OPIOID and opiate abuse/addiction medication assisted treatment (MAT) with Suboxone, Buprenorphine, Subutex.  PHYSICIAN level service.  PRIVATE.  Successful integration into daily life without fear and guilt.  START TODAY.

EXPECTATIONS ARE:  Come to your appointments, seek a counselor, use your medication as prescribed.  ABSOLUTELY no diversion is tolerated.  Not following the simple rules will leave you without medication.  The Clinic believes in great care, open listening, and the enjoyment of successful renewal to self and your family.  

DR WINTER – MEDICATION ASSISTED TREATMENT – OPIOID OPIATE ADDICTION – POST FALLS ID

PRIVATE

PERSONAL

PROFESSIONAL

PHYSICIAN LEVEL SERVICE

CALL 208-626-2949

NORTH IDAHO LOCATION – EASY ACCESS –

POST FALLS off I-90 Seltice

OPIOID and opiate abuse/addiction medication assisted treatment (MAT) with Suboxone, Buprenorphine, Subutex.  PHYSICIAN level service.  PRIVATE.  Successful integration into daily life without fear and guilt.  START TODAY.

ADDICTION – ABUSE – OVERUSE – OPIOIDS – SUBOXONE(R) – BUPRENORPHINE – CALL 208-626-2949 WHY WAIT ANY LONGER? Dr Winter POST FALLS

CALL ME…..

208-626-2949

WHY WAIT?

BUPRENORPHINE – Subutex(R) – Suboxone(R) – MAT TREATMENT – CALL 208-626-2949 – Dr Winter POST FALLS ID

  • OPIATE OVERUSE OR ADDICTION USE – buprenorphine
  • PRIVATE
  • PERSONAL
  • CONFIDENTIAL
  • PROFESSIONAL
  • CALL ME.  208-626-2949

OPIOID/OPIATE CLINIC – MED ASSISTED TREATMENT – CALL 208-626-2949 – Dr Winter POST FALLS ID

Information about Medication-Assisted Treatment (MAT)

 

Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies, which is effective in the treatment of opioid use disorders (OUD) and can help some people to sustain recovery.

More must be done to facilitate treatment options and the development of therapies to address OUD as a chronic disease with long-lasting effects. This means helping more people secure MAT, which requires us to break the stigma often associated with some of the medications used to treat OUD. It also requires us to find new and more effective ways to advance the use of medical therapy for the treatment of OUD.

There are three drugs approved by the FDA for the treatment of opioid dependence: buprenorphine, methadone, and naltrexone. All three of these treatments have been demonstrated to be safe and effective in combination with counseling and psychosocial support. Everyone who seeks treatment for an OUD should be offered access to all three options as this allows providers to work with patients to select the treatment best suited to an individual’s needs. Due to the chronic nature of OUD, the need for continuing MAT should be re‐evaluated periodically. There is no maximum recommended duration of maintenance treatment, and for some patients, treatment may continue indefinitely.

FDA-approved buprenorphine products approved for the treatment of opioid dependence include:

Bunavail (buprenorphine and naloxone) buccal film
Cassipa (buprenorphine and naloxone) sublingual film
Probuphine (buprenorphine) implant for subdermal administration
Sublocade (buprenorphine extended‐release) injection for subcutaneous use
Suboxone (buprenorphine and naloxone) sublingual film for sublingual or buccal use, or sublingual tablet.
Subutex (buprenorphine) sublingual tablet
Zubsolv (buprenorphine and naloxone) sublingual tablets

FDA-approved methadone products approved for the treatment of opioid dependence include:

Dolophine (methadone hydrochloride) tablets
Methadose (methadone hydrochloride) oral concentrate

FDA-approved naltrexone products approved for the treatment of opioid dependence include:

Vivitrol (naltrexone for extended-release injectable suspension) intramuscular

Back to Top

Announcements

Additional Resources

Bitnami